Rolapitant

Drug Profile

Rolapitant

Alternative Names: Rolapitant hydrochloride; SCH-619734; VARUBI; Varuby

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough; TESARO
  • Class Antiemetics; Ethers; Piperidines; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Discontinued Cough; Postoperative nausea and vomiting

Most Recent Events

  • 08 Aug 2017 Launched for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in Austria, Finland, United Kingdom and Denmark (PO)
  • 03 Jun 2017 Launched for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in Germany (PO)
  • 03 Jun 2017 FDA assigns PDUFA action date of 25/10/2017 for rolapitant (IV) for Chemotherapy induced nausea and vomiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top